Innoviva, Inc. INVA Cost Reimbursement — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Innoviva, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Innoviva, Inc.'s cost reimbursement — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Innoviva, Inc.'s cost reimbursement — revenue?
- Innoviva, Inc. (INVA) reported cost reimbursement — revenue of $0 in Q1 2026.
- How has Innoviva, Inc.'s cost reimbursement — revenue changed year-over-year?
- Innoviva, Inc.'s cost reimbursement — revenue decreased by 100.0% year-over-year, from $600K to $0.
- What is the long-term trend for Innoviva, Inc.'s cost reimbursement — revenue?
- Over 2 years (2023 to 2025), Innoviva, Inc.'s cost reimbursement — revenue has grown at a 44.1% compound annual growth rate (CAGR), from $1.3M to $2.7M.
- What does cost reimbursement — revenue mean?
- This metric represents the total revenue generated from cost reimbursement arrangements within the company's specific business segment. It reflects the recovery of expenses incurred during the delivery of specialized services or the management of strategic healthcare assets. Monitoring this revenue stream helps investors assess the company's ability to monetize operational support activities and recover costs associated with its broader portfolio of healthcare interests.